AI in Drug Discovery Market size was valued at USD 898.2 Mn. in 2021 and the total Insulation revenue is expected to grow by 29.5% from 2022 to 2029, reaching nearly USD 7104.46 Mn. The use of the Artificial Intelligence has been increasing in various sectors of Pharmaceutical Industry. AI models are used to determine relationship between the structural properties of chemical compounds and biological toxicity. AI is impacting drug discovery in new and previously unimaginable ways.Investors have largerly gravitated toward the hype throwing an un-precedented amount of funding toward Artificial Intelligence in Drug Discovery. Artificail Intelligence in Drug Discovery not only flash gene-sequencing work,but also trained to predict drug efficacy and side effects. By implementing AI solutions, the length of the clinical trial cycle is shortened, and the procedure is more efficient and accurate. As a result, stakeholders in the life science industry are becoming more and more interested in implementing these cutting-edge AI solutions in drug discovery procedures. The strategic alliances and collaborations between the largest AI-based drug discovery businesses and pharmaceutical corporations expanded from 4 partnerships in 2015 to 27 partnerships in 2020, according to Clinical Trials Arena data forecasts for 2021. The AI among top biopharmaceutical companies is a result of expanding interest in AI in the pharmaceutical industry and rising expenses on medication development. Modern algorithms are created by combining AI with cutting-edge biology and chemistry techniques, and this technology has the ability to move drug screening from the bench to the virtual lab without the need for a lot of experimental input or human labour.To increase the research power of immuno-oncology medications, metabolic disease therapies, cancer treatments, and many other therapeutic targets, the majority of sizable biopharmaceutical companies have started internal programmes or are partnering to develop AI platforms for drug discovery.
Scope of the Report:The report provides a comprehensive analysis of the global AI in Drug Discovery Market. This report estimates the market in terms of USD value from 2021 to 2029. The research contains In-depth analysis about the major factors that are driving and hampering the growth of the AI in Drug Discovery market across the world. The report includes a thorough segmental analysis based on offerings, Therapeutic insights and application. In-depth understanding of the potential of the AI in Drug Discovey market has gained from regional examination of the innovation,merger and acquisition, corporate operations, and market value. In addition, there is a separate section on the market structure. The section offers a thorough analysis of the major industry participants and their plans for growth in the world AI in Drug Discovey market. The Research aims to provide market participants with an overview of the AI in Drug Discovey Market. The study looks at the markets recent, ongoing, and predicted future changes. It also provides a simple analysis of complex data. New entrants, industry titans, and followers are some of the primary forces that actively and carefully perform research. The study displays the results of the PORTER and PESTEL analyses as well as probable outcomes of the microeconomic market elements. After accounting for internal and external variables that can have a favorable or unfavorable impact on the firm, decision-makers will have a clear futuristic perspective of the market. The market segmentation analysis and market size forecast in the research help investors better understand the dynamics and structure of the AI in Drug Discovey market. The report acts as a buyer's guide by clearly outlining the comparative analysis of the top AI in Drug Discovey businesses by price, financial position, product, product portfolio, growth strategies, and regional presence. To know about the Research Methodology :- Request Free Sample Report
AI in Drug Discovery Market Dynamics:Big Tech and Pharmaceutical companies investing together In order to use Microsoft's AI algorithms on the massive datasets used in pharma, Novartis and the computer company established a multi-year strategic agreement in 2019. The businesses said that in order to produce personalised medicine and improve cell and gene therapy, they intended to apply picture analysis and generative methods. In April, Nvidia, a company that makes graphics processing units and has been stepping up its AI efforts, teamed up with Schrödinger in an effort to speed up and improve the software's ability to forecast molecules.These aforementioned factors are greatly driving the Artificial Intelligence in Drug Discovery Market. Exscientia is one of many businesses formed in the last ten years around AI-based approaches to drug discovery and development, many of which have lately generated significant finance.Some of them are creating instruments to speed up the discovery of potential small-molecule medication candidates. For Instance,Recursion Pharmaceuticals, raised $436 million in its IPO, producing enormous volumes of customised data on cellular behaviour in the expectation that these may be mined using AI to provide biological insights that could guide the creation of novel medications. Additionaly IT firms like IBM, Microsoft, and Google are also participating in investing and having finanvial collaboration with the pharmaceutical companies for building up Artificial Intelligence in Drug Discovey Market. Technical Challenges In many ways, artificial intelligence and machine learning are already developed. The quality of data sets, however presents a substantial obstacle when using Artificial intelligence methods for drug development. Numerous data sets are further challenging factors,while it is generally acknowledged that cooperation is crucial to advancing the use of AI in drug discovery, challenging problems relating to data ownership and sharing confidentially need to be handled. The field currently lacks strong instances of promising leads from the start, and many current technologies have been verified retroactively. The search for quality over quantity in drug discovery Artificial Intelligence offer potential approaches in examininig the large number of aspects of the drug discovery at an early stage before the compounds need to be taken in laboratory.For Instance AstraZeneca has implemented “5R framework”to improve R&D PRODUCTIVITY.By implementing 5R framework,AstraZeneca reports has improve the use of Ariticial Intelligence in drug discovery by 19%.Partnering between Pharma Companies and Artificial Intelligence companies are definitely booming across the industry.For Instance, Weatherall points to a collaboration launched in 2019 between AstraZenca and Benevolent Artificial Intelligence , To discover new drugs for chronic kidney diseases and idiopathic pulmonary fibrosis.Artificial Intelligence with its ability to look at vast quantatites of existing data and learn patterns which are too complex for human to recognize can recognize and predict small molecules with the desirable properties, taking the computation skills to the next levels.For Instance,the Iktos,announced in March 2022 that it was applying its technology to a number of small molecule discovery programmes at Pfizer. It has also made collaboration with Merck ,KGaA,Almirall, which is a Barcelona based company working on treatments of skin diseases. There has been surge of interest in approaches based around generating data specifically with the Artificial Intelligence application in mind, for Instance, Insitro which was founded in 2018 are rapidly generating high quality biological data sets suitable for machine learning in drug Discovery creating a growth opportunities in Aritificial Intelligence in Drug Discovery Market.
Companies Date Deals involving in Companies creating growth opportunites of Artificial Intelligence in Drug Discovery Market. Recursion Pharmaceuticals Bayer
Bayer and Recursion Pharmaceuticals collaborated on the development of novel small-molecule therapeutics for the treatment of fibrotic illnesses using Recursion's AI-guided drug discovery platform in addition to its Series D investment round. Insitro,Bristol Myers Squibb
By creating prediction models of amyotrophic lateral sclerosis and frontotemporal dementia, Insitro will be able to identify prospective therapeutic targets using its machine-learning technology, the Insitro Human platform. The candidates chosen by Bristol Myers Squibb will next undergo further development. Roivant,Silicon Therapeutics
For $450 million, Roivant acquires Silicon, including its physics-based platform for in silico small-molecule drug design, which will be combined with machine learning strategies used by Roivant. Iktos,Pfizer
Iktos will use Pfizer's small-molecule programmes to implement its AI-driven de novo design software.
AI in Drug Discovery Market Segment Analysis:By Offering, the AI in Drug Discovery Market is segmented into Software and Services. In terms of market share, the services segment is anticipated to dominate the global AI in drug discovery services market in 2022 and to have the greatest CAGR between 2022 and 2029. The main reasons promoting the growth of this market segment are the advantages connected with AI services and the high demand for AI services among end users. However,the software segment too is parallely dominating the AI in Drug Discovery,For Instance many developing companies are focused on deep learnng innovative solutions and generative models which has enabled using existing data to design molecules that are optimized in silico to meet all the success criteria of the small molecules discovery project.For Instance,Makya is the first user friendly SaaS platform for AI-driven Novel Drug Discovery focused on Multi Parametric Optimization for Ligand and structure-based projects. By therapeutic insights , In 2021, the oncology sub-segment had the highest revenue share, exceeding 20.0%. As Human error is common in disease diagnosis, using AI systems can help with early disease identification. In recent years, AI has improved its ability to recognise diseases. Since lung cancer is typically discovered in its later stages, when survival rates are already quite low, earlier identification with the aid of AI systems provides to be beneficial in this situation. A Northwestern University researcher was effective in identifying lung cancer in scans where no radiologists would. In order to better diagnose COVID-19, numerous hospitals and institutions across Europe have joined forces by incorporating a sizable amount of anonymous data from multiple sources, they intend to create algorithms to analyse CT scans and train such algorithms to look for COVID symptoms. By Application, the AI in Drug Discovery Market is by application is segment into AI used in pharmacology, drug design, drug screening, drug repurposing,In which Ai used in drug design and drug screening segment dominate the market.According to MMR finding the AI used in Drug scrrening showed that 70% of anti microbial activity could accurately predict the toxic properties of the drug with only 4% of error rate.AI are widely used to find inhibitor molecule for specific protiens. Further the AI in drug Discovery are widely used in Clinical trials application and this segment is forecasted to dominate the market.The recent development of AI tools for the clinical trials during drug discoery have been ideal for recognizing diseases of patients, identifying gene targets and off targets.AI in drug discovery are used to identify and predict human relevant biomarkers of diseases to select and recruit specific patiemt population which has further increased the success rate of Clinical trials.
AI in Drug Discovery Market Regional Insights:In 2021, North America's revenue share was above 56.0%, which was the highest. The United States has been at the forefront of AI technology since its inception. Due to IBM's usage of their supercomputer "Watson" to win the game "Jeopardy," the business has since improved on the concept of AI. The tech sectors have made AI a significant component, and it is commonly used in a variety of fields, including the pharmaceutical industry. To accelerate medication research, design, and repurposing, major tech corporations in the United States have all partnered with esteemed institutions. Additionally, they are utilising AI to investigate disorders and draw pertinent conclusions that can enhance disease management. Thanks to the growing acceptance of smart cities in developing nations like India and China, the Asia Pacific AI in Drug Discovery market is expected to account for a sizeable portion of the global market. The market for AI In Drug Discovery is also expected to be driven by an increase in population in APAC nations.
AI in Drug Discovery Market Scope: Inquiry Before Buying
Global AI in Drug Discovery Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: USD 898.2 Mn. Forecast Period 2022 to 2029 CAGR: 29.5 % Market Size in 2029: USD 7104.46 Mn. Segments Covered: by Offering • Software • Service by Therapeutic insights • Oncology • Neurodegenerative Diseases • Cardiovascular Diseases • Metabolic Diseases • Infectious Diseases • Others by Application • Target Selection and Validation • Drug Screening and Lead Optimization • Clinical Studies • Preclinical studies
AI in Drug Discovery Market Key Players• IBM Watson • Exscientia • GNS Healthcare • Alphabet (DeepMind) • Benevolent AI • BioSymetrics • Euretos • Berg Health • Atomwise • Insitro • Cyclica FAQs: 1. What is the study period of the market? Ans. The Global AI in Drug Discovery Market is studied from 2017-2029. 2. What is the growth rate of AI in Drug Discovery Market? Ans. The AI in Drug Discovery Market is growing at a CAGR of 29.5% over forecast period. 3. What is the market size of the AI in Drug Discovery Market by 2029? Ans. The market size of the AI in Drug Discovery Market by 2029 is expected to reach at USD 7104.46 Mn. 4. What is the forecast period for the AI in Drug Discovery Market? Ans. The forecast period for the AI in Drug Discovery Market is 2022-2029. 5. What was the market size of the AI in Drug Discovery Market in 2021? Ans. The market size of the AI in Drug Discovery Market in 2021 was valued at USD 898.2 Mn.
1. Global AI in Drug Discovery Market: Research Methodology 2. Global AI in Drug Discovery Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global AI in Drug Discovery Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global AI in Drug Discovery Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global AI in Drug Discovery Market Segmentation 4.1 Global AI in Drug Discovery Market, by Offering (2021-2029) • Software • Services 4.2 Global AI in Drug Discovery Market, by Therapeutic insights (2021-2029) • Oncology • Neurodegenerative Diseases • Cardiovascular Diseases • Metabolic Diseases • Infectious Diseases • Others 4.3 Global AI in Drug Discovery Market, by Application Area (2021-2029) • Target Selection and Validation • Drug Screening and Lead Optimization • Clinical Studies • Preclinical studies 5 North America AI in Drug Discovery Market(2021-2029) 5.1 North America AI in Drug Discovery Market, by Offering (2021-2029) • Software • Services 5.2 North America AI in Drug Discovery Market, by Therapeutic insights (2021-2029) • Oncology • Neurodegenerative Diseases • Cardiovascular Diseases • Metabolic Diseases • Infectious Diseases • Others 5.3 North America AI in Drug Discovery Market, by Application Area (2021-2029) • Target Selection and Validation • Drug Screening and Lead Optimization • Clinical Studies • Preclinical studies 5.4 North America AI in Drug Discovery Market, by Country (2021-2029) • United States • Canada • Mexico 6 Europe AI in Drug Discovery Market (2021-2029) 6.1. Europe AI in Drug Discovery Market, by Offering (2021-2029) 6.2. Europe AI in Drug Discovery Market, by Therapeutic insights (2021-2029) 6.3. Europe AI in Drug Discovery Market, by Application Area (2021-2029) 6.4. Europe AI in Drug Discovery Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7 Asia Pacific AI in Drug Discovery Market (2021-2029) 7.1. Asia Pacific AI in Drug Discovery Market, by Offering (2021-2029) 7.2. Asia Pacific AI in Drug Discovery Market, by Therapeutic insights (2021-2029) 7.3. Asia Pacific AI in Drug Discovery Market, by Application Area (2021-2029) 7.4. Asia Pacific AI in Drug Discovery Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8 Middle East and Africa AI in Drug Discovery Market (2021-2029) 8.1 Middle East and Africa AI in Drug Discovery Market, by Offering (2021-2029) 8.2. Middle East and Africa AI in Drug Discovery Market, by Therapeutic insights (2021-2029) 8.3. Middle East and Africa AI in Drug Discovery Market, by Application Area (2021-2029) 8.4. Middle East and Africa AI in Drug Discovery Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9 South America AI in Drug Discovery Market (2021-2029) 9.1. South America AI in Drug Discovery Market, by Offering (2021-2029) 9.2. South America AI in Drug Discovery Market, by Therapeutic insights (2021-2029) 9.3. South America AI in Drug Discovery Market, by Application Area (2021-2029) 9.4. South America AI in Drug Discovery Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10 Company Profile: Key players 10.1 GNS Healthcare 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 IBM Watson 10.3 Exscientia 10.4 Alphabet (DeepMind) 10.5 Benevolent AI 10.6 BioSymetrics 10.7 Wipro 10.8 Euretos 10.9 Berg Health 10.10 Atomwise 10.11 Insitro 10.12 Cyclica